Clinical Trials Logo
  1. Home
  2. Angiosarcoma
  3. NCT02212015

Evaluation of Votrient in Angiosarcoma — EVA  

Angiosarcoma Clinical Trial

Official title:
Single-arm, Multicenter, Open Label Phase II Trial to Evaluate the Efficacy of Pazopanib in Combination With Paclitaxel in Advanced and Relapsed Angiosarcoma

Clinical Trial Summary

Open-label phase II trial investigating the efficacy and safety of the investigational combination of pazopanib and paclitaxel.

Clinical Trial Description

Open-label phase II trial investigating the efficacy and safety of the investigational combination of pazopanib and paclitaxel.This multi-center, open-label, prospective, single arm phase II study was designed to evaluate the clinical efficacy and safety of the experimental combination of pazopanib with paclitaxel in the treatment of patients with advanced or metastatic angiosarcoma.The safety evaluations (physical examination, laboratory checks as defined in protocol, toxicity/adverse event assessment according Eastern Cooperative Oncology Group version 4.0) are scheduled every cycle at day 1, 8, 15 and 29 (= day 1 of the next cycle). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02212015
Study type Interventional
Source Heidelberg University
Contact
Status Terminated
Phase Phase 2
Start date July 2014
Completion date July 1, 2020
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT04906876 - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Phase 2
Completed NCT01303497 - Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas Phase 2
Recruiting NCT02625389 - Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. Phase 4
Completed NCT04293289 - Boron Neutron Capture Therapy Using CICS-1 and SPM-011 for Malignant Melanoma and Angiosarcoma N/A
Recruiting NCT05859074 - A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer Phase 1
Not yet recruiting NCT02732678 - Dose-Finding of Propranolol in Combination With Metronomic Fixed Oral Cyclophosphamide Based on Bivariate Efficacy-tolerability Outcome in Patients With Locally Advanced or Metastatic Angiosarcoma: A Collaborative and Innovative Phase I-II Sequential Trial by the French Sarcoma Group (GSF/GETO) Phase 1/Phase 2
Recruiting NCT04055220 - Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas N/A
Recruiting NCT06375941 - Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars
Recruiting NCT05799612 - Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma Phase 1
Withdrawn NCT05116800 - Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Phase 2
Recruiting NCT01042379 - I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Phase 2
Active, not recruiting NCT01786889 - Identification, Molecular Epidemiology Angiosarcoma of the Liver France N/A
Active, not recruiting NCT02834013 - Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Phase 2
Active, not recruiting NCT03331250 - Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) Phase 2
Completed NCT02584309 - Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Phase 2
Not yet recruiting NCT06277154 - MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma Phase 2
Withdrawn NCT04607200 - AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma Phase 2
Completed NCT04518124 - Propranolol in Angiosarcoma Phase 2
Recruiting NCT05961761 - Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients Phase 2
Completed NCT00887809 - Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes Phase 2